Investigational pharmacology for low back pain by Chimes, Gary et al.
© 2010 Chimes et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Pain Research 2010:3 169–181
Journal of Pain Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
169
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/JPR.S9243
Investigational pharmacology for low back  
pain
Avinash K Bhandary1  
Gary P Chimes2  
Gerard A Malanga3 
1Department of Physical Medicine 
and Rehabilitation, 2Department of 
Physical Medicine and Rehabilitation, 
University of Pittsburgh Medical 
Center, Pittsburgh, PA, USA; 3New 
Jersey Sports Medicine Institute; 
Overlook Hospital;  Mountainside 
Hospital; Rehabilitation Medicine 
and Electrodiagnosis, St Michael’s 
Medical Center; Horizon Healthcare 
Worker’s Compensation Services, 
Blue Cross and Blue Shield Worker’s 
Compensation, Summit, NJ, USA
Correspondence:  Gary P Chimes 
Department of Physical Medicine and 
Rehabilitation, University of Pittsburgh 
Medical Center, Pittsburgh, PA, USA 
Tel +1 412 858 0337 
Fax +1 412 372 1493 
Email garypchimes@gmail.com
Study design: Review and reinterpretation of existing literature.
Objective: This review article summarizes the anatomy and pathogenesis of disease processes 
that contribute to low back pain, and discusses key issues in existing therapies for chronic low 
back pain. The article also explains the scientific rationale for investigational pharmacology 
and highlights emerging compounds in late development.
Results/conclusion: While the diverse and complex nature of chronic low back pain continues 
to challenge clinicians, a growing understanding of chronic low back pain on a cellular level has 
refined our approach to managing chronic low back pain with pharmacology. Many emerging 
therapies with improved safety profiles are currently in the research pipeline and will contribute 
to a multimodal therapeutic algorithm in the near future. With the heterogeneity of the patient 
population suffering from chronic low back pain, the clinical challenge will be accurately 
stratifying the optimal pharmacologic approach for each patient.
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Introduction
Low back pain (LBP) has reached epidemic proportions in Western societies with 
reported lifetime prevalence rates more than 70%.1 LBP is a musculoskeletal 
 symptom defined as discomfort in the lumbosacral region of the back. The dis-
comfort may or may not radiate to the legs, hips, and buttocks. LBP is considered 
acute if the discomfort persists 6 weeks or less and is considered chronic if persists 
longer than 12 weeks. While the population of patients suffering from LBP contin-
ues to expand, the clinical challenges of effectively treating back pain persist. This 
reflects the  multidimensional nature of LBP and heterogeneity of the population it 
affects. In the past decade,  emerging treatments and preventive approaches of care 
for conditions such as respiratory and circulatory diseases have been successful 
in reducing the cost of social security disability. This contrasts with LBP, where 
the population of disabilities beneficiaries continues to expand despite an array of 
therapeutic measures.2
Despite a substantial expansion in other therapeutic approaches, pharmacotherapy 
remains central to the management of LBP. Analysis of the United States national 
expenditures for back pain finds that the costs allocated to prescription medications 
have increased at a rate greater than any other service category, which includes  imaging, 
emergency department visits, and inpatient and outpatient services.3
Fortunately, there are promising emerging treatments that may help in  optimizing 
pharmacologic management. The focus of LBP pharmacology has shifted from 
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symptom-directed management to a better understanding of 
pain mechanisms on a basic science level. Disease modifica-
tion, molecular based pharmacologic targets, and biomarkers 
of disease processes are all new and exciting pathways for 
investigational pharmacology.
Investigational pharmacology for LBP is a topic 
of incre asing significance on clinical and fiscal levels. This 
article will look at common etiologies of back pain, review 
emerging treatments along the research pipeline (Figure 1), 
their scientific rationale, and the promise of their therapeutic 
possibilities.
Osteoarthritis-induced low  
back pain
LBP affects 80% of the world’s population. The common 
cold is the only disorder that occurs more frequently than 
LBP.4 The lumbar spine is a common site for symptomatic 
pain associated with osteoarthritis (OA), because it is a pri-
mary weight-bearing structure for most functional activities. 
Risk factors predisposing to osteoarthritis-induced LBP range 
from race and gender to biomechanics and age. Pharmaco-
logic treatment options for OA are diverse both in terms of 
mechanisms of action and delivery formulations. However, 
no single agent has been demonstrated to consistently offer 
both a high level of tolerability and sustained degree of 
efficacy across a broad OA patient population.5
Patient satisfaction is shifting to medications that provide 
an improved long-term prognosis rather than short-term 
symptomatic relief. This has allowed pharmacotherapeutic 
strategies to focus on the biology of osteoarthritis on a molec-
ular level in hopes to modify the disease and provide long-
term results with improved safety profiles. Scientific rationale 
behind emerging  pharmacology  centers on the  biomarkers of 
OA and will attempt to modify these  inflammatory mediators. 
The relationship between inflammation and angiogenesis 
and prevalence of synovositis in OA also provides clinical 
ground for experimental strategies.
Anatomy
Aside from the complex psychological component of pain 
perception and referred pain, the ambiguous nature of LBP 
is underpinned by the numerous potential pain contributors 
within the anatomy. Clinicians must travel a path of exclu-
sion, investigating the nature of disease processes, integrity, 
and the biomechanics of spinal anatomy before deciding 
upon the appropriate therapeutic regimen. Anatomic areas 
of interest include intervertebral discs, lumbar spinal nerves, 
sacroiliac and zygapophyseal joints (ZJ), muscles, ligaments, 
and tendons.
To locate the primary pain generator in LBP, physi-
cians must correlate clinical findings with the appropriate 
pathophysiologic process. A crucial step in understanding 
the pathophysiology of LBP was made with the description 
of the degenerative cascade by Dr William Kirkaldy-Willis. 
The degenerative process that transforms an anatomically 
succinct lumbar spine into a source of pain was described by 
Kirkaldy-Willis in a 3-phase process. The first phase, termed 
the dysfunction phase, described the low back in terms of 
functional units. Each functional unit is composed of a 3-joint 
complex consisting of an intervertebral disk and 2 ZJs. The 
dysfunction phase described the clinical presentation and pain 
produced by dysfunctionality of the 3-joint complex.6
1.   Licofelone (ML3000)
2.   Naproxcinod (AZD-3582)
3.   Lumiracoxib
4.   ADL5859, ADL5747
5.   Loperamide
6.   Salmon calcitonin
8.   Lacosamide
7.   Botulinum toxin
11.   Sativex
12.   Venlafaxine12.   Antidepressants
1.   COX/LOX inhibitor
Drug class Drug
2.   COX-inhibiting nitric oxide donator (CINOD)
3.   COX-2 inhibitor
4.   Delta opioid receptor agonist
5.   µ-opioid receptor agonist
6.   Antiresorptive pharmacology
8.   Ion channel (voltage and ligand gated) blocker
7.   Neurotoxin
9.   N-type calcium channel blocker 9.   Ziconotide, leconotide (CNSB004)
10.   TRPV1-agonis 10.   Transacin (Transdolor, NGX-4010)
11.   Cannabinoids
Figure 1 Pharmacology reviewed.
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The second stage, known as the unstable phase, described 
the pain generated from continuing stresses secondary to 
 dysfunction of the 3-joint complex during movement. The third 
phase, termed the stabilization phase, referred to pathologic 
changes in the lumbar spine that produce stiffness, immobil-
ity, and eventual autofusion of the spine.6 These pathologic 
changes include fibrosis of the 3-joint complex, osteophyte 
production and subsequent central spinal canal, lateral recess 
and neural foramen narrowing, which lead to the production 
radicular leg pain.
With the responsibility of truncal load dissipation, tor-
sion, flexion, and extension the interplay between lower 
back anatomic structures is significant. Abnormalities in 
pathoanatomic structures, such as muscle, tendon, ligament, 
or the sacroiliac joint produce poor postural control and 
altered kinematics that facilitate LBP. Two of the primary 
 anatomical components of mechanical LBP are the interver-
tebral disc and ZJ.
The essential components of disc-mediated pain include 
internal disc disruption (IDD), which is the most common, 
disc torsion, and infection of the intervertebral disc known 
as diskitis. Discogenic pain is mediated through the mixed 
autonomic and somatic fibers of the sinuvertebral nerve. 
The sinuvertebral nerve innervates the posterior annulus 
and adhering longitudinal ligament and normally penetrates 
the outer 1–3 mm of the annulus or outer third of the disk. 
The annulus is significant in that it is responsible for the 
 highest stress concentration during mechanical loading.
The ZJs, also commonly referred to as facet joints, are 
one of the most common sources of LBP.7 The ZJs are a 
pair of joints in the posterior aspect of the spine that bridge 
between the superior articular process of one vertebra and 
the inferior articular process of the vertebra immediately 
superior (Figure 2). The facets on the articular processes 
are covered by articular cartilage and a 1 mm thick fibrous 
capsule lined by synovial membrane, making this joint a 
true synovial joint. The function of the lumbar ZJ includes 
repetitive load transmission, stabilization of flexion and 
extension, and limiting axial rotation. Potential pain genera-
tors are interwoven throughout the complex neuroanatomy 
of the ZJ. Terminal branches of unmyelinated (Group 4) and 
thinly myelinated (Group 3) fibers are located throughout the 
synovium and periosteum. Nociceptors are found surround-
ing blood vessels near the synovium cells. In addition, the 
capsule of the ZJ is richly innervated with nociceptive and 
autonomic nerve fibers.8
Innervation of the ZJ begins with the spinal nerve at each 
lumbar spinal level, which divides into a ventral and dorsal 
Cross section of the zygapophyseal joint (ZJ)
Intervertebral disk
Vertebral body
Spinous process
Inferior articular process Superior articular process Zygapophyseal joint
Figure 2 Zygapophyseal joint.
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primary ramus. The dorsal ramus divides into 3 branches, 
and the most medial branch supplies sensory fibers to 2 facet 
joint levels. The sensory fibers supply the inferior portion of a 
posterior facet and the superior part of the joint capsule at the 
next lower level. Therefore, each ZJ is supplied by sensory 
nerves from spinal nerves from 2 different segments.9 The 
perception of pain originates from inflammation and resultant 
sensitization of unmyelinated sensory nerves present in the 
osteoarthritic joint. This network of sensory nerve innerva-
tion to the ZJ is complex and often overlaps, making lumbar 
spinal pain difficult to localize.
Pathogenesis
Osteoarthritis-induced LBP represents step-wise structural 
failure of the lumbar spine that ultimately leads to an ingrowth 
of nerves and blood vessels. Lumbar spinal pain related to OA 
of the ZJ is closely related to disk height for several reasons. 
The height of the annulus determines the separation between 
the neural arches of adjacent vertebrae, and annulus collapse/
bulging in old discs can lead to more than 50% of the com-
pressive force being resisted by the neural arch.10 With age 
and repetitive compressive loading, the trabecular network of 
the vertebral endplate sustains microdamage and allows for 
decompression of the adjacent nucleus, which subsequently 
transfers truncal load to the annulus. An irregular distribu-
tion of mechanical load throughout the disk ultimately shifts 
forces posteriorly to the ZJ and the ligmamentum flavum. 
The net result is that the posterior elements, particularly 
the ZJ, will bear a greater load, which contributes to further 
degeneration of the spine.
On a cellular level, disc degeneration occurs when an 
imbalance exists between the efforts of chondrocytes, the 
production of cartilaginous anabolic factors, and production 
of catabolic enzymes. Catabolic mediators include matrix 
metalloproteinases (MMP-3, MMP-13), inducible nitric 
oxide synthase (iNOS), interleukin-1-beta (IL-1B), and 
tumor necrosis factor (TNF-a).11 The catabolic pathways 
are induced by compressive forces, which also cause tissue 
hypoxia and bony matrix degeneration both of which are 
potent mediators of angiogenesis.
Angiogenesis is the proliferation of new blood vessels 
from preexisting blood vessels. Degeneration leads to inflam-
mation, which is mediated by macrophages that produce 
inflammatory mediators as well as produce factors that initi-
ate the angiogenic cascade. The association between osteo-
chondral angiogenesis and pain behavior may be explained 
by perivascular nerve growth or stimulation of subchondral 
nerves following loss of osteochondral integrity.12
Angiogenesis perpetuates inflammation by providing 
permeable channels for leukotreine ingress which secrete pro-
inflammatory factors. The sprouting network of  unmyelinated 
nerve growth or neo-innervation that follows angiogenesis 
is a crucial element in the generation of pain. Angiogenesis 
may introduce sensory nerves into the aneural cartilage, 
and inflammation can sensitize nerves present in the joint.13 
Therefore, a ‘normally’ insensate structure potentially 
becomes a candidate for pain in OA. This may also accelerate 
disease status via localized neurogenic inflammation.14
The symbiotic relationship between angiogenesis and 
inflammation occurs within the synovial membrane and is 
significant to the pathophysiology of OA. Increasing atten-
tion is being devoted to the contribution of synovositis in 
the pathology of OA. Synovositis is the result of an over 
expression of proinflammatory cytokines, such as IL-1B, 
and TNF, that drive degenerative catabolic activity. Thrombin 
is another protein in the synovial fluid which is a potential 
biomarker of synovial inflammation and is correlated with 
angiogenic factor VEGF expression.15 Synovositis has been 
identified in early and end-stage OA. Synovositis, therefore, 
although not a prerequisite for OA, may lead to a poor clinical 
outcome.13 Novel therapeutic interventions aiming to inhibit 
synovositis in OA may not only improve short-term symp-
toms but also reduce pain and disability in the long term.
Prostanoids and receptors
The development and severity of OA correlates with an 
increasing expression of cartilage-degrading enzymes, pros-
taglandins (PGs) and leukotrienes (LTs) in synovial fluid. 
The action of cyclooxygenase (COX) and 5-lipooxygenase 
(5-LOX) on arachidonic acid (AA) produces prostanoid 
enzyme products PGs and LTs. The COX enzyme exists 
in 3 isoforms COX-1, COX-2, and COX-3. Non-steroidal 
anti-inflammatory drugs (NSAIDs) pharmacologically inhibit 
both COX-1 and COX-2, producing substantial analgesia. 
The dual inhibition of NSAIDs prohibits the protective 
effect of PGs on gastric mucosa and leads to ulceration of 
the mucosa. Selective COX-2 inhibitors reduce PG forma-
tion, producing analgesia and inflammation relief. However, 
selective COX-2 inhibitors also have adverse effects on the 
cardiovascular (CV) system. The COX-3 isoform is a variant 
of COX-1 and has low enzymatic capability; its distribution 
and low abundance in the central nervous system and in 
periphery do not make this a compelling target for analgesia.14 
Inhibition of both COX-1 and COX-2 shifts AA metabolism 
towards the 5-LOX pathway, which leads to subsequent LT 
production (Figure 3).
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LTs are responsible for changes in vascular permeability 
that occur during acute inflammation.16 Therefore, LTs have 
been implied as contributing factors in NSAID induced 
gastropathy and are identified an inflammatory mediators 
along with PGs. The combination of 5-LOX inhibitors or 
LT receptor antagonists with NSAIDs has been reported to 
be beneficial not only in relieving pain and inflammation, 
but also in preventing or reducing NSAID induced gastric 
damage.17 Thus, the concept of dual inhibition (ie, COX 
and 5-LOX inhibition) has emerged as an alternative safe 
therapy for enhanced analgesic and anti-inflammatory effect 
with little or no gastric mucosal damage.18 Recently, dual 
inhibition was suggested to curtail the adverse CV effects 
otherwise reported with COX inhibition.19
Prostanoid related pharmacology
The quest for analgesia without adverse CV effects has been 
well covered since the worldwide withdrawal of Vioxx in 
2004 for its relation to myocardial infarction and stroke. 
Licofelone (ML3000) is a promising dual inhibitor of COX-1/
COX-2 and 5-LOX enzymes with anti-inflammatory and 
analgesic properties as well as an improved CV and gas-
trointestinal (GI) profile for the treatment of osteoarthritis. 
Licofelone has good oral bioavailability and reaches peak 
plasma level 3–4 hours after ingestion. It has a long half-life 
(approximately 11 hours), with the highest accumulations in 
liver, lung, kidney, heart, and intestine.20
Licofelone is currently in phase 3 trials and has been 
compared to NSAIDs (Naproxen) and selective COX-2 
inhibitors (Celcoxib) in terms of analgesic efficacy and 
safety profile. A 52-week trial was performed to determine 
the long-term tolerability and efficacy of licofelone compared 
with naproxen. This multicenter double-blind trial included 
patients with symptomatic OA of the knee (as defined by 
American College of Rheumatology guidelines) who had 
discontinued NSAID therapy 3–14 days prior to the baseline 
visit. Patients were randomized to receive licofelone, 100 
mg twice daily (n = 235), or naproxen, 500 mg twice daily 
(n = 229).21
Licofelone treatment was associated with a dose-dependent 
improvement in WOMAC pain scores from baseline. The 
efficacy of licofelone 200 mg was similar to that of naproxen 
during the study, with a trend towards greater efficacy at weeks 
26, 39, and 52. Mean changes in WOMAC pain scores, from 
the baseline value of 63.9 mm, were 27.1, 30.2, and 27.7 mm 
for licofelone 100 mg, licofelone 200 mg, and naproxen, 
respectively. Safety evaluation of the trial was evaluated by 
means of GI or CV adverse events. Laboratory parameters and 
vital signs were also recorded. The incidence of adverse events 
confirmed the superior long-term tolerability of licofelone 
Phospholipids
12-LOX
A B
COX (COX-1/COX-2)
15-LOX
5-LOX
5-HPETE
5-LOX
LTA42
LTA42 hydrolase
LTB4LTC4
LTD4
TXA2 PGD2
PGH2
PGG2
PGE2 PGF2a PGI2
LTE4
5-HETE
GST
Cyclooxygenase reaction
Activation of phospholipases
(PLC, PLD, PLA2)
Peroxidase reaction
Arachidonic acid
Figure 3 The cyclooxygenase (COX) pathway.
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over naproxen. The patients in the 100 and 200 mg licofelone 
treatment experienced fewer side effects than those in the 
naproxen group (59.2%, 56.3%, and 66.7%, respectively). In 
particular, lower frequencies of peripheral edema and aggra-
vated hypertension were recorded for licofelone compared 
with naproxen.21 These findings of reduced peripheral edema 
and hypertension suggest the dual inhibition mechanism of 
licofelone could be free from CV toxicity in OA patients, an 
adverse effect otherwise associated with selective COX-2 
inhibitors.22
To compare the efficacy and tolerability of licofelone with 
celecoxib in patients with knee OA, a 12-week multicenter, 
double-blind, parallel-group study was performed. Results 
indicated that licofelone, 200 mg twice daily, administered 
to 302 patients was as effective as celecoxib, 200 mg every 
day, given to 306 patients, with a similar frequency of GI 
adverse events in both the licofelone group (31.9%) and the 
celecoxib group (36.4%) with significantly fewer incidences 
of peripheral edema with licofelone as compared to cele-
coxib. Responders were quantified as those with a .30% 
improvement in WOMAC pain score from baseline. After 
12 weeks, responder rates in the licofelone and celecoxib 
groups were 77.2% and 77.8%, respectively.21
With a heterogeneous patient population, polypharmacy 
must be considered when pursuing ideal safety profiles in 
the pharmacologic treatment of OA. The demographic of 
patients suffering from OA and seeking analgesia with a low 
risk burden is growing. To further evaluate the risk burden of 
licofelone in a patient who is taking more than one medica-
tion, the safety profile of licofenole compared with naproxen 
was explored with the coadministration of aspirin 81 mg daily 
in a 4-week double-blind, randomized, endoscopy trial. The 
trial investigated the gastric and duodenal mucosal tolerabil-
ity, as assessed by endoscopy, of licofelone 200 mg bid and 
licofelone 400 mg bid compared with naproxen 500 mg bid 
therapy and placebo over a 4-week period in healthy volun-
teers. Data revealed that gastroduodenal ulcers of unequivocal 
depth developed in 20% of the volunteers receiving naproxen 
after 4 weeks, while no ulcers were reported in volunteers 
who received licofelone 200 mg or 400 mg. Lanza scores con-
firmed the significantly superior gastric tolerability of both 
licofelone doses compared with naproxen, and demonstrated 
the excellent gastric and duodenal tolerability of licofelone 
200 mg and 400 mg compared with placebo. In addition, the 
tolerability of the treatments did not appear to be effected by 
positive Helicobacter pylori status.23
Naproxcinod (AZD-3582) is the first in a new class of 
analgesic and anti-inflammatory drugs called  COX-inhibiting 
nitric oxide donators (CINODs). CINODs possess the 
 anti-inflammatory properties of NSAIDs through the 
 balanced inhibition of COX-1 and COX-2 while maintaining 
an improved GI and CV safety profile. The gastroprotective 
of CINOD comes from its nitric oxide donating ability. Nitric 
oxide increases gastric mucus and bicarbonate secretion, 
improves gastric mucosal blood flow, and inhibits the pro-
inflammatory activities of neutrophils and platelets.
Naproxcinod has completed 3 Phase III clinical studies 
conducted in the US, Canada, and Europe, which recruited 
more than 2,700 patients with OA of the knee and hip. Data 
extrapolated from the most recent phase III clinical trial for 
Naproxcinod is listed below. Three co-primary endpoints of 
the study compared the efficacy of naproxcinod 750 mg bid 
to placebo, in terms of the mean change between baseline 
and week 13 in the following scores: the WOMACTM pain 
subscale, the WOMACTM function subscale and the subject’s 
overall rating of disease status.24
In November 2008, a 13-week, double-blind, placebo and 
naproxen controlled trial in patients with OA of the hip took 
place. 810 patients were enrolled at 120 clinical centers in 
the United States, Canada, and Europe. Eligible patients 
had a diagnosis of primary osteoarthritis of the hip of at 
least 3 months in duration and were randomized on a 2:2:1 
basis to receive naproxcinod 750 mg bid, placebo bid, and 
naproxen 500 mg bid, respectively. Naproxcinod 750 mg bid 
showed good overall safety and tolerability. The percentage 
of patients who experienced one or more GI adverse events 
were the same for placebo and naproxcinod 750 mg bid at 
15.5%, compared with 19.2% for naproxen 500 mg bid. 
There was not a single serious CV or serious GI adverse 
event in the naproxcinod arm during the 13 weeks of the 
study. In addition, naproxcinod 750 mg bid showed a similar 
blood pressure profile to placebo, supporting earlier find-
ings suggesting its nondetrimental effect on blood pressure. 
Naproxinod 750 mg bid showed a clear reduction in systolic 
and diastolic blood pressure compared with naproxen 500 mg 
bid at all time points.24 In November 2009, NicOx announced 
that it received a filing communication from the US Food 
and Drug Administration (FDA) stating that the New Drug 
Application (NDA) for naproxcinod was accepted for filing. 
Pending the FDA’s approval, naproxinod could be poised for 
a US launch in late 2010.
Lumiracoxib is a novel COX-2 selective inhibitor devel-
oped for the treatment of OA. Lumiracoxib is the only acidic 
coxib (pKa:4.7), and is more selective for the COX-2 isoform 
compared with the COX-1 isoform than any other available 
selective COX-2 inhibitor.25 It is structurally  distinctive 
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from other COX-2 selective drugs by demonstrating a short 
 half-life (4 hours), but sustained pharmacokinetics and phar-
macodynamics in target tissue (eg, synovial fluid). These data 
suggest that lumiracoxib may be associated with reduced 
systemic exposure, while still reaching sites where COX-2 
inhibition is required for pain relief.26
The GI and CV safety profile of lumiracoxib was com-
pared with 2 non-steroidal anti-inflammatory drugs, naproxen 
and ibuprofen, in the Therapeutic Arthritis Research 
and Gastrointestinal Event Trial (TARGET). TARGET 
was a 52-week, international, multicenter, randomized, 
 double-blind, parallel-group study that compared 400 mg 
4 times daily (for OA recommended dose is 100 mg/day) with 
ibuprofen 800 mg 3 times daily and with naproxen 500 mg 
twice daily. The study indicated a significantly lower rate of 
ulcer complications in the group taking lumiracoxib in com-
parison with those taking nonselective NSAIDs. The lumira-
coxib group had significantly fewer ulcer  complications 
compared with those taking NSAIDs. Amongst those taking 
aspirin, there was no significant difference between lumira-
coxib and NSAID patients.14
After initially being launched in 2005, lumiracoxib (Prex-
ige) was withdrawn for liver toxicity. Novartis, the maker 
of lumiracoxib has identified a biomarker in patients with 
potential hepatic adverse effects and is currently planning 
resubmission of lumiracoxib with a companion diagnostic 
biomarker program to the FDA. To certify the molecular 
biomarker as an effective diagnostic test, Novartis has been 
working with the pharmacogenic experts at the FDA’s Vol-
untary Exploratory Data Submissions program for their feed-
back on utilizing the hepatic safety biomarker as a companion 
test. The resubmission of lumiracoxib could be the “first 
example” of a molecular diagnostic-based “drug rescue” in 
the industry.27 After the commercial re-launch of lumiracoxib 
with a widely certified diagnostic test is broadly introduced, 
Novartis is planning to conduct a prospective observational 
study to confirm the benefit of genetic testing.
Opiates and their receptors
The concern over the safety profile of traditional first-line 
agents such as cyclooxygenase-2 inhibitors and NSAIDs has 
limited their use in the pharmacologic management of LBP. 
In patients who cannot tolerate or have not benefited from 
the use of traditional first-line agents, conservatively dosed, 
time-based opioid therapy is becoming a popular alternative. 
The improved pain control of opioid therapy has allowed 
the patients suffering from osteoarthritis-induced LBP to 
become more functionally mobile. This is significant, since 
inadequate pain control has often left patients immobile, 
isolated to their home without sunlight which subsequently 
leaves them deficient in Vitamin D. Among the patients with 
spinal disorders, The National Medical Expenditure Panel 
Survey showed a 108% increase in opioid prescriptions from 
1997 through 2004. The combination of increasing use and 
higher drug prices resulted in a 423% inflation-adjusted 
increase in expenditures.28
Opioids bind to opioid receptors in the central nervous 
system and other tissues. Opioid receptors are G-protein 
coupled receptors acting on GABAergic neurotransmission. 
There are three principal classes of opioid receptors, mu, 
kappa, and delta. In addition the opioid receptor-like receptor 
1 (ORL1) is an important analgesic target in those who have 
developed tolerance to mu-opioid agonists.
Clinicians today are finding themselves in a difficult posi-
tion when it comes to prescribing opiates for their patients 
suffering from OA due to side effects such as nausea, depen-
dence, hyperalgesia, hypogonadism, respiratory depression, and 
physical dependence.2 The increasing trend to rely upon opioid 
therapy as an adjunctive therapy for the treatment of a disease 
process as far reaching as OA, poses the potential to create 
broad societal impacts. Emerging strategies in utilizing opioids 
in the pharmacological management of LBP focus on reducing 
the adverse effects produced by centrally penetrating opiates. 
Adverse effects of opiate use, such as respiratory depression and 
constipation, and potential for dependence/abuse are associated 
with mu-receptor agonists. To circumnavigate around these 
unwanted effects of mu-opioid receptor agonists, delta opioid 
receptors, which possess a favorable safety profile, are being 
targeted. In addition, central mu-opioid receptor agonists are 
being reformulated to intra-articular and topical forms.14
Pharmacology targeting the delta-opioid receptor (DOR) 
may provide analgesic efficacy without the common side 
effects of mu-opioid receptor agonists. Emerging DOR 
biology has indicated that stimulus-dependent (pain, inflam-
mation) trafficking of DOR from cytoplasm to cell surface 
appears to modulate apparent efficacy of agonists. Thus, delta 
ligands have low analgesic efficacy in acute pain models but 
show robust analgesia efficacy in a variety of chronic pain 
conditions accompanied by inflammation.29 Based on these 
findings the biopharmaceutical company Adolor has devel-
oped two delta compounds, ADL5859 and ADL5747. In 
October 2009, Adolor in collaboration with Pfizer initiated a 
Phase 2a proof-of-concept study of ADL5859 and ADL5747 
in osteoarthritis patients.30 Another route for providing  opiate 
analgesia without the side effects of  centrally acting opi-
ates is the anti-diarrheal drug Loperamide. In addition to its 
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 anti-diarrheal capabilities, Loperamide is a mu-opiate receptor 
agonist that does not penetrate the blood-brain barrier. When 
mu-opiate receptors are stimulated, they release potassium 
ions, which cause hyperpolarization of the cell membrane, 
and makes the neuron less excitable. The release of potassium 
ions also reduces the calcium ion influx in the terminal end 
of the neuron, which significantly reduces neurotransmit-
ter release. A neuron with a hyperpolarized cell membrane 
and  diminished ability to release neurotransmitters cannot 
 effectively relay pain signals. The development of topical and 
intra-articular formulations of loperamide have shown effi-
cacy as a peripherally selective opiate analgesic agent in post 
operative, inflammatory, and bone cancer pain models.31,32
Antiresorptive pharmacology
Salmon calcitonin (SCT) is an anti-resorptive agent that has 
been available for over 30 years. SCT is approved for the treat-
ment of post-menopausal osteoporosis, bone associated pain, 
and metabolic bone disease. SCT is commercially available as 
an injectable and as a nasal spray. A new oral formulation has 
been recently developed, and data from the first clinical trials 
indicate a potential utility not only in osteoporosis but also in 
osteoarthritis. Recent interest in SCT in the management of 
OA is due to its potential chondro-protective capabilities and 
analgesic effects. While the kinetics of calcitonin-induced pain 
relief have not been conclusively shown, potential mechanisms 
include an endorphin-mediated effect through the elevation of 
endogenous B-endorphin levels, centrally mediated pain relief 
via central nervous system binding sites, and stimulation of 
descending spinal serotonergic pathways.33
Clinical and pharmacological trial data have been largely 
focused on the analgesic efficacy of calcitonin as nasal spray 
(SCT-NS) and as an injectable treatment. Injectable SCT has 
been shown to be superior to placebo for pain relief in acute 
vertebral fractures.34 The analgesic effects of SCT-NS in 
vertebral fracture associated pain syndromes have also been 
shown in a double blind, placebo controlled study.35 Overall, the 
analgesic effects of both nasal spray and injectable preparations 
are comparable. The oral preparation of SCT has been shown 
to improve bioavailability and provide higher systemic levels 
of SCT. In Phase II trials, oral SCT has shown improvements 
in OA pain.36 Currently, Novartis and Nordic Bioscience are 
evaluating oral SCT (SMC021) in a Phase III trial for OA.
Botulinum toxin
The mechanism of pain relief provided by botulinum toxin 
(BoNT) has generated interest after clinical studies indicated 
that onset of pain relief occurred sooner than muscle spasm 
relief in studies evaluating BoNT injection for cervical dys-
tonia.37 This led to the investigation that pain relief provided 
by BoNT was separate from its ability to produce reversible 
muscle paralysis through inhibition of acetylcholine.
Animal studies have indicated multiple mechanisms 
for the anti-nociceptive properties of botulinum toxin type 
A (BoNTA). Possible mechanisms include a reduced rest-
ing discharge of muscle spindles after injection of BoNTA 
into skeletal muscles,38 which may theoretically diminish 
central sensitization. In central sensitization, wide-range 
function neurons of the spinal cord erroneously perceive 
non-nociceptive input (such as that from muscle spindles) 
as nociceptive.39 In cell cultures and animal studies, BoNTA 
diminishes the release of pain neurotransmitters such as sub-
stance P, calcitonin gene-related peptide, and bradykinin.40
In paraspinal compartment syndrome, BoNTA injection-
 induced atrophy of bulky paraspinal muscles relieves 
 compression of nerves and vascular structures and reduces 
ischemic pain. The evidence for BoNTA in the relief of 
osteoarticular pain has been encouraging. In a double blinded, 
randomized, placebo controlled study, administration of 
BoNTA into paraspinal muscles using a novel technique 
 produced significant pain relief in 60% of patients with 
chronic refractory back pain. However, this study was lim-
ited by a small sample size (n = 31).41 In a larger (n = 75) 
prospective, randomized open labeled study with a 14 month 
follow-up, a similar yield of pain relief was seen (53%). 
Among initial responders, 91% continued to respond over 
the length of the study.42 Currently, the Walter Reed Army 
Medical Center is holding a Phase IV trial to evaluate the 
analgesic efficacy of BoNTA in the management of patients 
suffering from chronic LBP. Botulinum neurotoxin therapy 
of chronic LBP is an off-label use and is not approved by the 
US Food and Drug Administration.
Neuropathic pain
Chronic LBP is highly prevalent in Western societies. Large 
epidemiological studies show that 20%–35% of patients 
with back pain suffer from a neuropathic pain component. 
Presently, chronic lumbar radicular pain is the most common 
neuropathic pain syndrome.1 The revised definition from 
the International Association for the Study of Pain states 
neuropathic pain is “pain initiated or caused by a primary 
lesion or dysfunction in the nervous system”.43 This definition 
signifies a shift from the traditional view that neuropathic 
LBP only relates to radiculopathy. Neuropathic pain is 
 comprised of a complex interplay between peripheral and 
central  mechanisms of pain modulation.
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The complex nature of neuropathic pain has currently 
left most therapeutic needs unmet. Neuropathic pain can 
be divided into central and peripheral components. The 
term ‘central’ refers to the brain and spinal cord. Central 
neuropathic pain refers to pain initiated or caused by 
a primary lesion or dysfunction of the central nervous 
system.44
Anatomically, central pain may originate in any lesion 
along the neuraxis located in the dorsal horn, the ascend-
ing pathways throughout the spinal cord and brain stem, 
the thalamus, the subcortical white matter, and the cerebral 
cortex. The most common occurrences of central pain stem 
from traumatic spinal cord injuries, strokes, and multiple 
sclerosis. Other causes of central pain include brain tumors, 
epilepsy, syringomyelia, and spinal cord infractions.45
Central neuropathic pain syndromes appear to originate 
from the reorganization of central somatosensory process-
ing. Central neuropathic pain is associated with neuronal 
plasticity. Neuronal plasticity refers to the anatomical and 
neurochemical changes that can occur within the central 
nervous system. These changes facilitate and maintain a ‘pain 
state’ long after the initial injury. This neuronal plasticity 
or increased excitability reflects a sensitization of neurons 
within the dorsal horn following peripheral tissue damage. 
This sensitization is characterized by increased spontaneous 
activity of the dorsal horn neurons, a decreased threshold and 
an increased responsivity to afferent input, and cell death in 
the spinal dorsal horn.46
The peripheral component to neuropathic pain pertains 
to peripheral nerve injury. In peripheral nerve injury, new 
adrenergic receptors may develop leading to an increased 
sensitivity to pain. In addition to an increased amount of 
adrenergic receptors, damaged nerves may possess differ-
ent depolarization characteristics and dysfunctional sodium 
channels. These structural aberrations lead to an increased 
excitability which leads to increased pain transmission.
Pharmacological treatment of neuropathic pain to date is 
directed towards the symptomatic management of hallmark 
features such as spontaneous pain, mechanical and cold allo-
dynia, hyperalgesia, and hyperpathia. Recently, an improved 
molecular-based understanding behind the mechanisms 
of neuropathic pain has provided better insight and led to 
development of new therapeutic approaches.
The neuroanatomy of the central and peripheral nervous 
system and the neuropathic pain spectrum is beyond the scope 
of this article. Therefore, we will focus on key molecular 
events and cellular processes in neuropathic pain that provide 
rationalization for investigational pharmacology.
Pathogenesis
The neuropathic component to LBP is a not a result of a 
single pathophysiological mechanism, but the final product 
of altered peripheral, spinal and supraspinal processing. 
The initiation of neuropathic LBP may be caused by lesions 
of nociceptive sprouts within the degenerated disc (local 
neuropathic), mechanical compression of the nerve root 
(mechanical neuropathic root pain), or by action of inflam-
matory mediators (inflammatory neuropathic root pain) 
originating from the degenerative disc even without any 
mechanical compression.1
Ion channel (voltage and ligand gated) 
blockers
Hyperexcitability in small and large peripheral sensory 
nerves acts as an important driving mechanism for neuro-
pathic pain and can account for the initiation and maintenance 
of central hyperexcitability.43 Changes in the expression 
and activity of several voltage-gated sodium, potassium, 
and calcium channels have been highlighted after nerve 
injury.47 These changes in the expression, trafficking, and 
redistribution of ion channels after inflammation or nerve 
injury are considered to account for unstable oscillations of 
membrane potential, abnormal firing and the generation of 
ectopic activity in afferent nerves.48 Therefore, the blockage 
of voltage-gated ion channels is therapeutic in regulating 
sensory neural excitability.
Lacosamide is an anticonvulsant with neuronal antihyper-
excitability properties that is being evaluated as an emerging 
treatment for neuropathic pain. By blocking voltage-gated 
sodium channels, Lacosamide has been reported to incon-
sistently produce significant reduction in pain measures 
compared with a placebo in clinical trials.47 Currently, Lacos-
amide is in a Phase II trial to assess the continued efficacy and 
safety of ascending doses in subjects with chronic refractory 
neuropathic pain.
Another voltage-gated ion channel of interest in the phar-
macologic treatment of neuropathic pain is the calcium chan-
nel. The influx of calcium ions through voltage-gated calcium 
channels has an established role in axonal potential formation 
and neurotransmitter release by primary sensory neurons. Aber-
rant calcium channel physiology and activity has also become 
a focus of attention in the search for targets for therapeutic 
interventions that prevent or alleviate neuropathic pain.
Ziconotide is the first in a new class of non-opioid 
analgesics known as N-type calcium channel blockers 
(NCCBs), which target pre-synaptic calcium channels on 
nerves that ordinarily transmit pain signals.49 Intrathecal 
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ziconotide  infusion was approved by the FDA in 2004 for 
the  management of severe chronic pain in patients who were 
not effectively managed with systemic analgesics, adjunctive 
therapies, or intrathecal morphine. Ziconotide is the synthetic 
equivalent of a naturally occurring conopeptide found in the 
venom of a marine snail known as Conus magus, a predatory 
sea creature that attacks its prey with harpoons loaded with 
a paralytic poison.50
Intrathecal ziconotide is regarded as a broad-spectrum 
analgesic effective as a monotherapy and in conjunction 
with opioids in the management of neuropathic pain, and to 
those suffering from intractable pain. In a double-blinded ran-
domized, placebo-controlled trial, patients (169 ziconotide, 
86 placebo) with severe chronic nonmalignant pain unre-
sponsive to conventional therapy were treated over a 6-day 
period in an inpatient hospital setting. The mean percentage 
change in visual analog scale of pain intensity (VASPI) 
score from baseline was 31.2% and 6.0% for ziconotide- and 
placebo-treated patients, respectively.51 Due to its narrow 
therapeutic index, ziconotide has been associated with side 
effects such as postural hypotension, mental status changes 
and hallucinations. However, significant adverse events are 
less apt to occur when the drug is slowly titrated gradually 
over 3 weeks or longer.52
The intrathecal administration and adverse effects of 
ziconotide has limited its clinical utility. Recently, another 
n-type calcium channel blocker, leconotide (CNSB004) has 
drawn considerable pharmacologic interest. In animal studies, 
the anti-hyperalgesic effect of leconotide was comparable to 
that of ziconotide. When compared with ziconotide, the side 
effect profile of leconotide (locomotor activity and vascular 
responses) was clearly better than that of ziconotide.53 The 
maximum no side-effect dose of leconotide caused 51.7% 
reversal of hyperalgesia, compared with 0.4% for the highest 
no side-effect dose of ziconotide.54 In addition, leconotide 
was effective when administered intravenously, suggesting 
an effective alternative delivery method for n-type calcium 
channel blockers other than intrathecal administration.53 
In the treatment of neuropathic pain, the development of 
non-opioid analgesics offers new, powerful therapeutic pos-
sibilities. These initial findings demonstrate the therapeutic 
potential of leconotide, a calcium channel blocker with an 
improved side-effect profile and the ability to be administered 
through a new route.
In addition to voltage-gated ion channels mentioned 
above, the large family of transient receptor potential (TRP) 
vanilboid channels are also pharmacological targets in the 
treatment of neuropathic pain. Transient receptor potential 
vanilloid channel 1 (TRPV1), a non-selective cation channel, 
has garnered significant pharmacological interest. On noci-
ceptive neurons, TRPV1 is gated by capsaicin, noxious heat 
(.45°C), acidic pH (,5.3), and is regulated by a variety of 
inflammatory mediators (eg, bradykinin and PGE2).47 Emerg-
ing strategies focus on TRPV1 agonists and antagonists as 
a molecular focal point in neural sensitization caused by 
mediators of inflammation and nerve injury.55
Capsaicin, a TRPV1-agonist, has been investigated, 
and reports have been promising. When capsaicin binds to 
TRPV1, it causes the channel to open below 37°C. Prolonged 
activation of these neurons by capsaicin depletes presynaptic 
substance P, one of the body’s neurotransmitters for pain 
and heat. Capsaicin mimics a burning sensation that leaves 
the nerves that host a TRPV1 receptor overwhelmed. These 
nerves are unable to report pain for an extended period of 
time due to a depletion of neurotransmitters. This depletion 
of neurotransmitters leads to a reduction in pain sensation. 
Low dose capsaicin cream (0.025% and 0.075%) has been 
a moderately efficacious over the counter topical treatment 
for chronic pain for decades. These low dose capsaicin 
creams must be applied multiple times a day and have 
caused a burning pain each time they are applied leading to 
non compliance.
Transacin (Transdolor, NGX-4010) is a high concentra-
tion (8%) dermal patch that delivers a therapeutic dose of 
capsaicin during a 60-minute application. Transaicin (NGX-
4010) has been well tolerated and efficacious in reducing 
pain in a number of neuropathic pain conditions including 
a Phase III study in patients with post-herpetic neuralgia.56 
Although trials have been limited, due to the difficulty of 
blinding high-concentration capsaicin, multiple studies both 
open label and double blinded, suggest that a 1-hour appli-
cation of NGX-4010 can reduce neuropathic pain in a safe 
and efficacious manner. Neuropathic pain reductions with 
NGX-4010 can be maintained with repeated administrations 
over a 1-year period.57
Cannabinoids
In 1997, the British Medical Association (BMA), NIH, and 
American Medical Association published reports concluding 
that cannabinoids have a role as adjuvant analgesics for pain 
conditions refractory to standard drugs.47
The analgesic success of cannabinoids compounds is 
centered on targeting 2 receptors within the  endocannabinoid 
system, cannabinoid receptor 1 (CB1) and cannabinoid 
receptor 2 (CB2). CB1 receptors are widely distributed in 
the  central nervous system and peripheral sensory neurons, 
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whereas CB2 receptors have been found in peripheral 
 tissues including tissues of the immune system and keratino-
cytes with limited expression in sensory and central nervous 
system cells.58
Studies indicate that cannabinoids such as ∆9-tetrahydro-
cannabinol (∆9-THC) activate both CB1 and CB2 receptors 
and facilitate cellular inhibitory mechanisms that attenuate 
the hyperexcitability involved with neruopathic pain. CB1 
receptors are responsible for mediating the analgesic effects 
in the brain and spinal cord, while peripheral CB1 receptors 
are involved with pain transmission from the peripheral 
nervous system.59 CB2 receptors are also responsible for 
pain modulation in the spinal cord.
Multiple clinical trials have shown that treatment utilizing 
cannabinoid compounds reduce neuropathic pain; however, 
they also produce adverse effects such as euphoria, dizzi-
ness, and sedation. Recent studies have shown selective 
targeting of peripheral and spinal CB1 and CB2 receptors 
are promising targets for analgesia because they may avoid 
the psychoactivity of brain CB1 receptor activation and may 
allow the administration of doses that produce a greater 
analgesic effect with reduced psychoactivity.60
Cannabinoid receptor pharmacology
Sativex, an oral form of (∆9-THC) in the preparation of an 
oralmucosal spray has shown promise as an adjuvant anal-
gesic in the treatment of refractory peripheral neuropathic 
pain in a Phase II/III, 5-week, double blinded, randomized, 
placebo-controlled study (324). This study suggests a syn-
ergistic interaction between the endocannabinoid and opioid 
receptor system in the treatment of neuropathic pain. The 
majority of adverse events associated with Sativex use in 
this study were categorized as being mild or moderate. Cur-
rently, Sativex is an investigational drug in the United States 
and is being developed as an adjunctive analgesic treatment 
for patients with advanced cancer whose persistent pain has 
not been adequately relieved by opioid therapy. Studies have 
also shown CB2 selective agonists to modulate pain without 
central CB1-like side effects.61
Although many studies involving cannabinoids in the 
treatment of neuropathic pain have been promising, there are 
many challenges that remain. Barriers that need to be over-
come prior to utilizing cannabinoid receptors in the treatment 
of neuropathic pain include an improved definition of thera-
peutic indications, a better understanding of the therapeutic 
balance between cannabinoid receptors and opioid receptors, 
and how to provide effective analgesia while minimizing side 
effects. Another major barrier to the accepted therapeutic use 
of cannabinoids in clinical practice is the associated stigma 
that comes hand in hand with this drug class.62
Anti-depressants and B-mimetics
Despite the close association between chronic pain and 
depression, we now know that the pain-relieving effect 
of antidepressants is independent of their mood-elevating 
properties.63,64 The primary mode of action is an  interaction 
with pathways extending through the spinal cord from 
serotoninergic and noradrenergic structures in the brain 
stem and midbrain. Other pathways for analgesia provided 
with antidepressants include actions on opioids, adrenergic, 
GABA, and N-methyl-D-aspartate receptors.
Tricyclic antidepressants (TCAs) such as amitryptiline, 
nortryptyline, imipramine, and desipramine are regarded as 
first-line drugs when treating LBP.65 In addition to blocking 
the reuptake of norepinephrine and serotonin, TCAs block 
neuronal membrane ion channels and interact with adenosine 
and NMDA receptors. The utilization of TCAs for neuropathic 
pain has been limited due to anticholinergic side effects includ-
ing blurred vision in glaucoma patients, urinary retention, con-
stipation, and dry mouth. Antihistaminergic side effects such 
as oversedation and weight gain can also preclude its use.66
Venlafaxine is a serontonin-norepinephrine reuptake 
inhibitor (SNRI) and may be considered a suitable alterna-
tive to TCAs in relieving neuropathic pain. Venlafaxine does 
not have anticholinergic and antihistaminergic blocking side 
effects.67 Venlafaxine blocks the reuptake of serotonin at 
lower doses; when used in higher doses it blocks the reuptake 
of norepinephrine. When utilized at a high dose there has been 
concern with Venlafaxine producing hypertension.66 Dulox-
etine, another SNRI commonly used in painful neuropathy, 
does not have these effects.
Recent studies investigating the mechanism of antidepres-
sants in alleviating neuropathic pain revealed that activation 
of B-adrenergic receptors (B2-AR) plays a critical role. In a 
neuropathic pain model, the absence of a B2-AR suppresses 
the analgesic effects of chronic antidepressant treatment.68,69 
Preclinical studies have reported that chronic direct stimu-
lation of B2-AR by agonists may relieve neuropathic pain 
symptoms in a murine neuropathic pain model.70–72 Drugs that 
belong to the class of Beta two–adrenergic receptors include 
albuterol, terbutaline, fenoterol, salmeterol, ritodrine, and 
isoprenaline among others. These drugs are widely used and 
have well described adverse effects. Reports on B-mimetics 
potential as a neuropathic pain treatment are encouraging, 
and require randomized, controlled, prospective and blinded 
studies for further evaluation.
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Conclusion
Unified by the urgency to meet the therapeutic needs of the 
many that suffer from LBP and provide pain relief with a 
lower risk burden, the pharmacological landscape for the 
treatment of chronic LBP is changing as rapidly as any other 
field in medicine. At the epicenter of this investigational 
boom is an improved understanding of the biology of pain 
at a cellular level, safer drug profiles, new routes for drug 
delivery and novel molecular based therapeutic targets.
The therapeutic challenge of treating LBP stems from 
treating a pain that is maintained through nociceptive and 
neuropathic mechanisms, and abnormalities in the excit-
ability of central and peripheral pathways. These factors 
compounded with a diverse patient population have led to 
the need for an improved pharmacotherapeutic regimen. This 
review identified several emerging drugs in clinical Phases 
II and III, and attempts to provide some insight on how the 
drug development process is providing viable solutions for 
managing the complexities of LBP.
As the multimodal approach to managing LBP continues to 
evolve, our reliance on pharmacotherapy to play a significant role 
in the treatment algorithm remains constant. The heterogeneity of 
the LBP population prohibits a single drug from revolutionizing 
the treatment of LBP, and it is difficult to predict which drug or 
drugs will establish themselves as the most efficacious. However 
with the promise of the investigational pharmacology noted in 
this paper, there is no reason to believe that a larger, safer, and 
improved therapeutic armamentarium is not forthcoming.
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